BANK VONTOBEL/PUT/BIOGEN IDEC/250/0.01/21.06.24 | Delayed Deutsche Boerse AG 02:03:38 03/06/2024 pm IST | ||
| 0.23 EUR | -4.17% |
|
| 1 month | -25.00% | ||
| 3 months | -20.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 03/24/03 | 0.23 | -4.17% |
| 31/24/31 | 0.24 | -17.24% |
| 30/24/30 | 0.29 | -12.12% |
| 29/24/29 | 0.33 | +10.00% |
| 28/24/28 | 0.3 | +3.45% |
Delayed Quote Deutsche Boerse AG
Last update June 03, 2024 at 02:03 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VU9CS2 |
| ISIN | DE000VU9CS22 |
| Date issued | 03/07/2023 |
| Strike | 250 $ |
| Maturity | 21/06/2024 (18 Days) |
| Parity | 100 : 1 |
| Emission price | 0.16 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.56 € |
|---|---|
| Lowest since issue | 0.134 € |
| Spread | 0.01 € |
| Spread % | 4.18% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
224.9
USD
Average target price
284.8
USD
Spread / Average Target
+26.60%
- Stock Market
- Warrants
- Warrant
